◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › K › KURA

Kura Oncology Inc (KURA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-17

Kura Oncology Inc (KURA) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 260 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, KURA reported $67M in revenue and ($279M) in net income.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Interactive charts & full statements → Open the KURA valuation workbench →

KURA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Revenue	$77M	$67M	$54M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—	—
Gross Profit	$73M	$67M	$54M	($1M)	($1M)	($1M)	$0M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—
Gross Margin %	94.7%	99.9%	100.0%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($318M)	($304M)	($193M)	($166M)	($140M)	($131M)	($92M)	($67M)	($63M)	($36M)	($28M)	($24M)	($12M)	$0M	$0M	$0M	$0M	$0M	$0M
Operating Margin %	-411.9%	-449.9%	-358.6%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income	($297M)	($279M)	($174M)	($153M)	($136M)	($130M)	($90M)	($63M)	($60M)	($35M)	($28M)	($23M)	($11M)	$0M	$0M	$0M	$0M	$0M	$0M
Net Margin %	-384.3%	-413.0%	-322.9%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA	($292M)	($276M)	($169M)	($150M)	($135M)	($129M)	($89M)	($67M)	($63M)	($36M)	($28M)	($24M)	($12M)	$0M	$0M	$0M	$0M	$0M	$0M
Earnings Per Share (EPS)	$-3.36	$-3.18	$-2.02	$-2.08	$-2.03	$-1.97	$-1.69	$-1.51	$-1.72	$-1.52	$-1.47	$-2.28	$-2.69	$-0.01	$-0.01	$-0.00	$-0.00	$-0.00	$-0.01
Shares Outstanding (M)	89M	88M	86M	73M	67M	66M	53M	42M	35M	23M	19M	10M	4M	5M	5M	5M	5M	5M	5M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KURA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$21M	$18M	$17M	$21M	$15M	$14M	$54M	$0M
Gross Profit	$21M	$18M	$17M	$18M	$15M	$14M	$54M	$0M
Gross Margin %	98.8%	96.6%	100.0%	84.5%	100.0%	100.0%	100.0%	—
Operating Income (EBIT)	($73M)	($79M)	($86M)	($80M)	($73M)	($65M)	($22M)	($60M)
Operating Margin %	-349.8%	-431.5%	-497.6%	-385.5%	-475.3%	-458.6%	-41.7%	—
Net Income	($68M)	($73M)	($81M)	($74M)	($66M)	($57M)	($19M)	($54M)
Net Margin %	-327.3%	-401.5%	-467.2%	-357.2%	-432.5%	-407.1%	-35.7%	—
EBITDA	($66M)	($73M)	($80M)	($74M)	($66M)	($57M)	($17M)	($54M)
Earnings Per Share (EPS)	$-0.77	$-0.83	$-0.92	$-0.85	$-0.75	$-0.66	$-0.22	$-0.63
Shares Outstanding (M)	89M	89M	88M	88M	88M	87M	87M	87M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KURA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Cash from Operations (CFO)	($112M)	($64M)	$134M	($125M)	($110M)	($105M)	($70M)	($55M)	($49M)	($28M)	($25M)	($18M)	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Capital Expenditures (CapEx)	$6M	$7M	$0M	$0M	$1M	$1M	$2M	$2M	$2M	$2M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($117M)	($71M)	$134M	($125M)	($111M)	($106M)	($72M)	($57M)	($51M)	($31M)	($25M)	($18M)	$0M	$0M	$0M	$0M	$0M	$0M	$0M
FCF Margin %	-152.1%	-104.8%	248.4%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KURA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($63M)	($86M)	$117M	($81M)	($29M)	($72M)	$269M	($43M)
Capital Expenditures (CapEx)	$1M	$0M	$2M	$3M	$1M	$0M	$0M	$0M
Free Cash Flow (FCF)	($63M)	($86M)	$115M	($83M)	($30M)	($72M)	$269M	($43M)
FCF Margin %	-302.8%	-470.7%	663.1%	-400.9%	-197.8%	-511.9%	498.8%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KURA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$588M	$738M	$760M	$449M	$456M	$534M	$647M	$242M	$182M	$96M	$70M	$87M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Cash & Cash Equivalents	$70M	$149M	$224M	$37M	$52M	$91M	$325M	$26M	$16M	$11M	$10M	$15M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Total Liabilities	$539M	$564M	$347M	$52M	$36M	$27M	$36M	$23M	$21M	$16M	$13M	$5M	$5M	$0M	$0M	$0M	$0M	$0M	—
Total Debt (Short + Long-Term)	$11M	$11M	$11M	$11M	$11M	$2M	$9M	$8M	$8M	$7M	$15M	$7M	$3M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$48M	$174M	$414M	$397M	$420M	$507M	$611M	$219M	$161M	$80M	$57M	$82M	($3M)	$0M	$0M	$0M	$0M	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KURA viewer.

Other Companies in BIOTECHNOLOGY

SVRA · Savara Inc — $1 billion
OBX · Obsidian Therapeutics, Inc. Common Stock — $1 billion
JBIO · Jade Biosciences, Inc. — $1 billion
MLTX · MoonLake Immunotherapeutics — $1 billion
GLUE · Monte Rosa Therapeutics Inc — $1 billion
JANX · Janux Therapeutics Inc — $1 billion
ANL · Adlai Nortye Ltd. American Depositary Shares — $1 billion
ATTO · Attovia Therapeutics, Inc. Common Stock — $1 billion

← KUN All “K” companies KURE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.